Karin Walker
Director/Board Member at CYCLACEL PHARMACEUTICALS, INC.
Net worth: 11 106 $ as of 31/05/2024
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Paul McBarron | M | 63 | 22 years | |
Christopher Henney | M | 83 | 18 years | |
Brian Schwartz | M | 52 | 4 years | |
Gene Kinney | M | 55 | 12 years | |
Daniel Welch | M | 66 | - | |
Spiro Rombotis | M | 65 | 27 years | |
Lars Ekman | M | 74 | 12 years | |
Tran Nguyen | M | 50 | 11 years | |
Richard Collier | M | 70 | 12 years | |
Samuel Barker | M | 81 | 10 years | |
Michael J. Malecek | M | 58 | 5 years | |
Randy Fawcett | M | - | - | |
Paula Cobb | F | 51 | 5 years | |
Wagner M. Zago | M | 51 | 12 years | |
Brandon Smith | M | 50 | 4 years | |
Oleg Nodelman | M | 47 | 5 years | |
Robert Spiegel | M | 73 | 6 years | |
Shane Cooke | M | 61 | 12 years | |
Dennis Selkoe | M | 80 | 11 years | |
Kenneth Ferguson | M | 68 | 2 years | |
Yvonne M. Tchrakian | F | - | 10 years | |
Hideki Garren | M | 60 | 3 years | |
Carol Karp | F | 71 | 8 years | |
Helen Kim | F | 61 | 2 years | |
Michael Bachner | M | - | 2 years | |
William Dunn | M | 54 | 1 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Louis Lange | M | 72 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 19 years |
Geoff Duyk | M | 64 | 18 years | |
Arthur Levinson | M | 73 | 4 years | |
Nicholas Khadder | M | 50 | 6 years | |
Jonas Grossman | M | 50 | 2 years | |
Dale B. Schenk | M | 66 | 4 years | |
Andrew McDonald | M | 50 | 1 years | |
Samir Kaul | M | 50 | 6 years | |
Carole Piwnica | F | 66 | 12 years | |
Patrick Pichette | M | 61 | 3 years | |
Karl Härfstrand | M | 66 | 9 years | |
Arthur William Homan | M | 64 | 5 years | |
Gary Loeb | M | 54 | 2 years | |
Michael Rice | M | 59 | 1 years | |
Sanjiv Patel | M | 50 | 2 years | |
Jennifer Zibuda | F | - | 3 years | |
David Dobkin | M | 45 | 1 years | |
John Steven Ziegler | M | 65 | - | |
Barry Dennis | M | 59 | - | |
Kenneth Lee | M | 76 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 7 years |
Tamara L. Tompkins | F | 59 | 7 years | |
Nam Hai Chua | M | 79 | - | |
Judy Chiao | M | 64 | 17 years | |
Tara Nickerson | M | 51 | 6 years | |
Abdullah bin Khalifa Al Thani | M | 63 | 7 years | |
Joseph M. Davie | M | 84 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 3 years |
Caryn McDowell | F | 54 | 1 years | |
Martin Koller | M | 73 | 4 years | |
Joel Velasco | M | - | - | |
Krishna R. Polu | M | 50 | 4 years | |
Sarah Noonberg | M | 56 | 1 years | |
Cynthia Smith | F | 55 | 5 years | |
James Young Richardson | M | 57 | - | |
Radhika Tripuraneni | M | 44 | 4 years | |
David B. Mcninch | M | 55 | - | |
Rebecca Lucia | F | 52 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 1 years |
Mary Ellen Sillivos | F | - | 7 years | |
Peter M. Strumph | M | 59 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 10 years |
Matthew Panuwat | M | 47 | 1 years | |
Jason Raleigh | M | 47 | 5 years | |
Amartya Basu | M | - | 3 years | |
Courtney Phillips | F | 49 | 2 years | |
Louis Yu | M | 73 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 1 years |
Jeffrey H. Knapp | M | 58 | 7 years | |
Peter P. Boynton | M | 69 | - | |
Kenneth F. Boehm | M | - |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 4 years |
Thomas Shenk | M | 77 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 5 years |
Robert F. Venteicher | M | 78 | 6 years | |
Peter Hutt | M | 89 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 8 years |
David C. McCaleb | M | 70 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 10 years |
Peter G. Milner | M | 68 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 17 years |
Dan Spiegelman | M | 65 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 11 years |
Thomas L. Gutshall | M | 85 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 15 years |
Barbara McNeil | M | 83 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 14 years |
Anne-Marie S. Duliege | M | 64 | 9 years | |
Anne Champsaur | M | - |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 3 years |
Douglas T. Sheehy | M | 57 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 5 years |
Steven Mills | M | 68 | 1 years | |
Shay Weisbrich | F | 71 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 1 years |
Jennifer Hodge | F | 55 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 7 years |
Bruce Philip Pritchard | M | 51 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 2 years |
Mario Neutel Soares Portela | M | 62 | 3 years | |
Michael T. Sweeney | M | 63 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 4 years |
Philip Wells | M | - |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 1 years |
David Banks | M | - |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 4 years |
Jeryl Hilleman | F | 67 | 4 years | |
Santo Costa | M | 78 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 8 years |
Huang I-Zu | M | - |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 6 years |
Mark Kirschbaum | M | 63 | 4 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 65 | 68.42% |
Ireland | 31 | 32.63% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Karin Walker
- Personal Network